News & Events

News

news

26 July 2021

Da Volterra Announces First Patient Randomized in Phase 3 Clinical Trial Evaluating the Gut Microbiome Protector DAV132 in Patients with Hematologic Malignancies

• World’s first phase 3 study of a microbiome protector, conducted as part of the European COMBACTE-NET program …

events

29 June 2021

Jean De Gunzburg speaker at the 6th Microbiome Movement – Drug Development Summit on June 30 at 18:40 CEST

The 6th Microbiome Movement – Drug Development Summit is THE must-attend conference for microbiome drug developers. It is the perfect…

news

28 June 2021

Da Volterra strengthens its intellectual property for novel microbiome protectors

Da Volterra, a late-stage biopharmaceutical company developing novel intestinal microbiome-protective therapies, announced today that it has significantly strengthened its patents…

events

10 May 2021

Da Volterra is attending ChinaBio® Partnering Forum on May 12-14, 2021

ChinaBio® Partnering Forum is the largest and most productive life science partnering event in China. During the digital portion of…

events

03 May 2021

Da Volterra attending MEET2WIN European Oncology Partnering Convention on May 6-7, 2021

MEET2WIN offers conferences addressing topical issues in oncology with internationally renowned speakers. The European Oncology Partnering Convention is entirely dedicated…

events

20 April 2021

Florence Séjourné speaker at the JPIAMR Therapeutics workshop on April 20, 2021 at 13:30 CET

As AMR is an increasingly serious threat to global public health and threatens the effective prevention and treatment of infections,…

news

06 April 2021

Da Volterra Receives FDA Fast Track Designation for its Novel Microbiome Protector DAV132

• FDA Fast Track Designation has been granted to DAV132 for the prevention of Clostridioides difficile infection, a life-threatening…

events

15 March 2021

Da Volterra attending BIO-Europe Spring® Digital on March 22-25, 2021

The “must-attend” BIO-Europe event series has gone digital, and continues to grow, proving its importance and relevance to the life…

news

08 March 2021

New review published in Drug Discovery Today highlights the crucial role of the intestinal microbiome in health and disease and the need for microbiome protectors

Da Volterra is pleased to present the latest publication of the team on the role of the gut microbiome and…

news

03 February 2021

Da Volterra Receives first Authorizations from Regulatory Authorities in EU Countries to Initiate its Phase 3 Clinical Trial Evaluating the Microbiome Protector DAV132 in Patients with Hematologic Malignancies

• World-first phase 3 study of a microbiome protector • Da Volterra becomes a pioneering late-stage clinical company…